364results about How to "Effective therapy" patented technology

Method and system for providing basal profile modification in insulin therapy for use with infusion devices includes periodically monitoring the analyte levels of a patient for a predetermined period of time in order to determine, based on the monitored analyte levels, an appropriate modification factor to be incorporated into the underlying basal profile which was running at the time the periodic monitoring of the analyte levels were performed.

According to an aspect of the present invention, a medical device is provided, which comprises the following: (a) a hollow elongate body (e.g., a elongate cylinder, such as a needle) having distal and proximal ends; and (b) a rotatable member comprising a tissue morselizer and an elongate shaft (e.g., an auger-like tissue-drilling bit). In the devices of the present invention, the elongate shaft is disposed within the hollow elongate body and cooperates with the hollow elongate body to (i) advance material (e.g., morselated tissue) toward the proximal end of the hollow elongate body when the shaft is rotated in a first direction, and (ii) advance material (e.g., a therapeutic agent and / or a bulking agent) toward the distal end of the hollow elongate body when the shaft is rotated in a second direction that is opposite the first direction. According to another aspect of the invention a method of treatment is provided that comprises: (a) inserting the a medical device like that above into the tissue of a patient; (b) morselizing and removing tissue from within the patient while rotating the shaft in a first direction, thereby creating a void within the patient; and (c) introducing a therapeutic agent and / or a bulking agent into the void.

A compact, neck massager configured as a collar-type device adapted to be worn about a persons neck and adapted for providing the most effective natural relaxation therapies, namely gentle vibration and soothing heat to the neck and spine is disclosed. The device generally comprises a collar sculpted to fit comfortably around the neck and secured by flexible straps with connectable ends to facilitate removable attachment of the device around the user's neck. The collar includes a housing containing an electric motor powered alternatively by a battery or AC power source. The electric motor is adapted with an output shaft having an eccentric mass for converting rotational movement of a motor into a vibration movement for transmission to the cervical area through the housing. The device further includes a heating band disposed on the inner surface thereof for selectively transmitting heat to the cervical area. A control circuit is provided to enable the user to selectively vary the power supplied between the electric motor and heating element thereby varying the transmission of therapeutic vibration and heat to the neck. The electrical components are configured to function as an RLC circuit such that system oscillates between heat and vibration thereby maximizing therapeutic benefits.

The invention is directed to an intravaginal staple for occluding a female patient's uterine artery in the treatment of a uterine disorder such as fibroids, DUB, PPH, uterine bleeding after caesarian delivery and the like. The intravaginal staple includes an occluding bar having a pressure applying surface and at least one and preferably two tissue penetrating legs which are provided with protuberances which help to retain the staple leg within the penetrated tissue. At least part of the staple is preferably formed of bioabsorbable material so that it will in part self destruct at a preselected time period by separation of staple components caused by the bioabsorption of a bioabsorbable portion of the staple. The staple deployment system may be provided with elongated handles and staple deploying mechanisms on the distal ends of the handles to drive the legs of the staple into the tissue bundle about the uterine artery so that pressure applied by the occlusion bar occludes the uterine artery.

A method includes coupling electrodes to a patient's head and identifying whether any of the electrodes form a functional set, such that a desired therapeutic effect is achieved when the two or more electrodes deliver a total amount of current to the patient regardless of what portion of the total amount of current each respective electrode carries. One or more constant current sources are provided, each having a supply and return terminal, which supply and return equal amounts of current at any given time. The constant current source(s) are coupled to the electrodes in such a manner that each supply terminal and each return terminal is coupled to no more than the electrodes of a single one of the functional sets, if any, or to a single one of the electrodes not included in one of the functional sets.

Novel chimeric fusion proteins comprising immunodominant epitopes of GAD and insulin are provided. Also provided are immunomodulatory methods for the use of such proteins for both the prevention and treatment of Type 1 diabetes mellitus. The chimeric fusion proteins of the invention are useful in predicting risk of onset of Type 1 diabetes, determining prognosis of Type 1 diabetes patients early in disease progression, and in evaluating patients for suitability as recipients of transplants of pancreatic cells or tissues. The administration of the proteins of the invention in accordance with the immunomodulatory methods of the invention results in beneficial effects on disease development and severity in patients suffering from or predicted to be at risk of developing Type 1 diabetes, as well as on the outcome of transplants of pancreatic cells or tissues in Type 1 diabetes patients.

A treatment device which uses cold red and infrared radiation for the photodynamic stimulation of cells, especially cells of human tissue. The described device produces a constant energy radiation by the use of semiconductor and / or laser diodes, which furthermore radiate light in several separate wavelengths due to a special operation mode. With help of sensors the advanced controller system is able to test the patients for the needed radiation doses in order to avoid overstimulation. Furthermore the radiation openings in the applicators are advantageously covered with a polarization filter, whereby the absorption in the irradiated tissue is increased. The basic equipment consists of a standpillar, with which machine applicators are connected with a jointed arm. The machine applicators are adapted for the treatment of large area tissues, for example, the back of humans. The standpillar is freely movable on wheels and includes a control mechanism, whereby the various parameters for therapy can be adjusted and switched ON and OFF. The standpillar is also connected to a hand applicator designed for the treatment of small tissue areas, e.g., acupuncture points. Another version of the hand applicator is especially devised for dental treatment, whereby the head piece of the hand applicator can be connected with an expander containing an optical fiber. Photodynamic substances are introduced into tissue to be treated, which enhances the effects of light irradiation by the inventive device.

This invention relates generally to bifunctional molecules including (a) a TGFβRII or fragment thereof capable of binding TGFβ and (b) an antibody, or antigen binding fragment thereof, that binds to an immune checkpoint protein, such as Programmed Death Ligand 1 (PD-L1), uses of such molecules (e.g., for treating cancer), and methods of making such molecules.

The present invention concerns chimeric cancer therapeutic molecules comprising a targeting moiety and an anti-cell proliferation moiety. The anti-cell proliferation moiety may comprise a cytotoxic agent or an apoptosis-inducing factor, in specific embodiments. In particular embodiments, the anti-cell proliferation mechanism of the chimeric molecules comprises apoptotic pathways. In additional embodiments, the chimeric molecules of the present invention provide sensitivity to chemotherapy in a cell that is resistant to the chemotherapy.

The present invention relates to a method of treating cancer in a patient comprising administering to the patient therapeutically effective amounts of:a) a compound of formula A:or a pharmaceutically acceptable salt thereof, wherein R1-R4, p, and q are as defined; and(b) an erbB inhibitor that inhibits erbB-1 or erbB-2 or erbB-3 receptor or a combination thereof. The method of the present invention addresses a need in the art with the discovery of a combination therapy that shows evidence of being a more effective therapy than previously disclosed therapies.

Real-time and individualized disease monitoring is central to rapidly evolving medical sciences and technologies, but for the vast majority of patients, disease progression and treatment are monitored only in an irregular and discontinuous fashion. Consequently, disease progression and relapse are often allowed to proceed too far before they are detected, compromising the possibility of any effective treatment. For one patient, this can mean becoming refractory to the few early drug treatments that are available; for another, missing early detection may be deadly. This invention provides a method for the detection of early signals of disease and recovery thereof comprising a universal yet personalized health-monitoring solution using cell phones or other wearable smart device data that generate extensive real-time data. The invention further provides a system and method to provide answers to a variety of questions related to the patient health status and health trajectory. Its flexibility and generality is designed for a preferred application to rare disorders and rare questions for which other analytical system are lacking.

This invention relates generally to bifunctional molecules including (a) a TGFβRII or fragment thereof capable of binding TGFβ and (b) an antibody, or antigen binding fragment thereof, that binds to an immune checkpoint protein, such as Programmed Death Ligand 1 (PD-L1), uses of such molecules (e.g., for treating cancer), and methods of making such molecules.

The present invention provides an apparatus for photodynamic therapy and fluorescence detection, in which a combined light source is provided to illuminate an object body and a multispectral fluorescence-reflectance image is provided to reproduce various and complex spectral images for an object tissue, thus performing effective photodynamic therapy for various diseases both outside and inside of the body.For this purpose, the present invention provides an apparatus for photodynamic therapy and photodetection, which provides illumination with light of various wavelengths and multispectral images, the apparatus including: an optical imaging system producing an image of an object tissue and transmitting the image to a naked eye or an imaging device; a combined light source including a plurality of coherent and non-coherent light sources and a light guide guiding incident light emitted from the light sources; a multispectral imaging system including at least one image sensor; and a computer system outputting an image of the object tissue to the outside. Thus, the apparatus for photodynamic therapy and photodetection of the present invention can effectively perform the photodynamic therapy and photodetection by means of the combined light source capable of irradiating light having various spectral components to an object tissue and the multispectral imaging system capable of obtaining images from several spectral portions for these various spectral ranges at the same time, thus improving the accuracy of diagnosis and efficiency of the photodynamic therapy.

An apparatus for treating urinary incontinence, comprising a node; a support section adapted for providing urethral support attached to the node; and, an anchoring section adapted for resisting movement of the apparatus attached to the node; wherein the node is no longer than 30% of the entire length of the apparatus comprising the node, support section and the anchoring section together.

A pelvic support unit is coupled to a base by a powered vertical force actuator mechanism. A torso support unit, which is affixed to the patient independently of the pelvic support unit, is connected to the base by one or more powered articulations which are actuable around respective axes of motion. Sensors sense the linear and angular displacement of the pelvic support unit and the torso support unit. A control unit is coupled to these sensors and, responsive to signals from them, selectively control the displacement actuator and articulation(s). Wheel modules are independently powered to both rotate and steer, and, responsive to the control unit, are capable of rolling the exercise device in a direction of travel intended by the patient.

To maximize and maintain the antioxidant or pro-oxidant state for foods, beverages, personal care products, cosmetics, nutritional supplements, reagents, analytical standards, medical device formulations, pharmaceutical preparations or drags, the present invention discloses methods and devices to control redox equilibrium of such preparations throughout the processing steps and storage prior to, or at, the time of administration or use. The preparations (solid or liquid form) can then be stored in a redox-controlled container, package or applicator as described in the specification. Foods, beverages, personal care products, cosmetics, nutritional supplements, reagents, analytical standards, medical device formulations, pharmaceutical preparations and drugs stored in reactive oxidation states can be activated and stabilized by electrical voltages applied with a small battery and electrodes designed into the applicator, container or package.

The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and / or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.

The invention described herein provides a structure for growing isolated differentiable human mesenchymal cells, which includes a three-dimensional matrix of fibers. The matrix serves as an implantable scaffolding for delivery of differentiable human mesenchymal cells in tissue engineering. The invention further provides compositions that contain the three-dimensional matrix of fibers seeded with isolated differentiable human mesenchymal cells, wherein the matrix forms a supporting scaffold for growing the isolated differentiable human mesenchymal cells, and wherein the differentiable human mesenchymal cells differentiate into a mature cell phenotype. The invention further provides methods of preparing the implantable nanofiber matrix scaffolding seeded with differentiable human mesenchymal cells for use in tissue engineering.

Devices and methods whereby therapeutic agents may be injected into distinct organ locations in a minimally invasive manner. Most preferably the devices and methods employ a video-assisted thorascopic system (VATS) to enable a physician in real time to visually identify a distinct organ location into which therapeutic agent is to be injected. In particularly preferred forms, devices are provided for injecting a therapeutic agent into a tissue site which include a proximal handle, and a tubular barrel distally extending from the handle. The barrel has an injection needle at a distal end thereof which is most preferably angled relative to the barrel's elongate axis. The internal space of the barrel is sized and configured to receive a cartridge containing a therapeutic agent to be injected into the tissue site. A plunger assembly and injection trigger assembly are provided so as to cause the plunger to expel a predetermined volume of the therapeutic agent from the cartridge to the needle and thereby allow injection thereof to the tissue site in response to operation of the trigger assembly.

The present invention relates to the identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratory Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies retaining RSV-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Finally, the invention provides for diagnostic and therapeutic methods employing the antibodies and nucleic acids of the invention.

Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.

The present invention is directed to methods and compositions for blocking the effect of the intronic inhibitory splicing region of intron 7 of the SMN2 gene. The compositions and methods of the instant invention include short oligonucleotide reagents (e.g., oligoribonucleotides) that effectively target sites in the SMN2 pre-mRNA, thereby modulating the splicing of SMN2 pre-mRNA to include exon 7 in the processed transcript. The short target regions are 8-mers and 5-mers and also include the identification of a single nucleotide base that is essential for initiating a long distance stearic inhibitory interactions as well as novel targets distant from intron 7 which block the intronic inhibitory splicing of the same. These short target regions and concomitant inhibitory blocking oligonucleotides are less expensive and easier to manufacture and are small enough to cross the blood brain barrier.

A massaging device includes a motor integrated with a housing, a shaft for transmitting the motor motion, a treatment head attachable to the shaft. The rotational speed of the motor can be measured as part of a control circuit. The rotational speed provides an actual value to the control circuit. A setpoint of the rotation speed of the motor can be manually adjusted. The control circuit is designed so that the current supplied to the motor is controlled depending on the difference between the instantaneous actual value and the selected setpoint.

Disclosed embodiments describe a volar plate generally for use treating distal volar fractures. The volar plate is designed in accordance with anatomical features and is generally Y-shaped, having a wider distal head portion that tapers to a narrower proximal body portion. A plurality of holes in the distal head of the volar plate allow for fixation means to fix the position of bone fragments with respect to the volar plate. The plurality of holes in the distal head basically form two substantially non-linear rows, with the distal row generally curving inward proximally and the proximal row generally curving outward distally such that the fixation means inserted through the holes generally converge. A central cavity may be located in the proximal body of the volar plate to promote bone growth, and mounting screws may border the central cavity on either side to provide secure support. Additionally, K-wire holes may be included which are visually linked to corresponding holes in the distal head.

A method of treating cancer in a patient comprising administering to the patient an amount of oxaliplatin in combination with radioactively doped particle, characterised in that the two therapies when introduced into the patient have a synergistic anticancer effect.

Disclosed here are simple, non-invasive screening methods for diagnosing endometriosis, in particular, the type that is resistant to conventional progestin and progesterone therapy. Biomarkers for identifying subjects with endometriosis are disclosed. Alternative therapeutic methods with reduced side effects and compositions for treating endometriosis are also disclosed.